Cardiovascular Events After ICI Therapy “Common” in Lung Cancer
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
New research suggests that genetic susceptibility to lung cancer is greater in women, and a family history of cancer predicts lung cancer risk.
Research suggests that patient decision aids are useful to patients with cancer exploring first-line treatment options.
Listening to music during chemotherapy infusions improved cancer patients’ moods and reduced levels of distress in a recent study.
Dysphagia-optimized IMRT improved swallowing function, when compared to standard IMRT, in patients with head and neck cancer.
Results of a phase 3 trial suggest that tanezumab can reduce pain in cancer patients, but the drug is no longer under development.
Lung cancer patients treated with immune checkpoint inhibitors experience worse immune-related adverse event survival than other cancer patients.